Moreover, clinical trials have shown that second-line treatment with anti–PD-1 or anti-PD-L1 antibodies may even be effective in patients with no PD-L1 expression on their tumor or immune cells (4), whereas patients with high PD-L1 expression sometimes fail to respond to anti–PD-1/PD-L1 therapy (5). The gene discussed is CD274; the disease is neoplasm.